Blog Posts - Sovaldi™ (sofosbuvir)



Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5

-- High Cure Rates Observed Across a Range of Genotypes -- VIENNA, Austria--(BUSINESS WIRE)--Apr. 25, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from two studies evaluating the safety and efficacy of investigational uses of...
by Hepatitis C Research and News on Apr 25, 2015

EMA recommends avoidance of certain hepatitis C medicines and amiodarone together

Press Release 24/04/2015 Concomitant use may increase risk of slow heart rate and related problems The European Medicines Agancy (EMA) has confirmed a risk of severe bradycardia (slow heart rate) or heart block (problems with conduction of elec...
by Hepatitis C Research and News on Apr 24, 2015

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C

-- Sovaldi Part of First All-Oral Treatment Regimen for Genotype 2 Patients in Japan -- -- 96 Percent Cure Rates and Shortened, 12-Week Course of Therapy -- FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 26, 2015-- Gilead Sciences, Inc. (Nasdaq:GILD) t...
by Hepatitis C Research and News on Mar 26, 2015

B.C covers two curative hepatitis C drugs

Monday, March 23, 2015 3:00 PM VICTORIA - British Columbia is providing public drug plan coverage of two new, often curative, hepatitis C drugs effective March 24, 2015, announced Minister of Health Terry Lake today. People with hepatitis C will be...
by Hepatitis C Research and News on Mar 25, 2015

FDA Safety Alert on Sovaldi/Harvoni Label Change

You are receiving this message as a subscriber to the FDA hepatitis electronic list serve. The purpose of the list serve is to relay important information about viral hepatitis-related products and issues, including product approvals, significant lab...
by Hepatitis C Research and News on Mar 21, 2015

NICE rejection looms for Sovaldi

Published on 16/06/14 at 10:35am In a draft recommendation published today NICE is asking Gilead for more information on its new hepatitis C pill Sovaldi (sofosbuvir) – and is currently not minded to recommend the treatment for NHS England funding...
by Hepatitis C Research and News on Jun 16, 2014

Gilead’s Efforts to Ensure Patient Access to Sovaldi® for Chronic Hepatitis C

Gilead Sciences Policy Position Key points: Approved by the U.S. Food and Drug Administration in December 2013 and by the European Commission in January 2014, Gilead’s Sovaldi (sofosbuvir) represents a therapeutic advance in the treatment of...
by Hepatitis C Research and News on Jun 14, 2014

Hepatitis C drug is approved: A drug treatment for chronic hepatitis C is to be made available to NHS patients in Scotland

By Press Association, 9 June 2014 11.00pm. Updated: 10 June 2014 5:41am. The Scottish Medicines Consortium (SMC) has approved sofosbuvir for restricted use within the NHS. The SMC said its use addresses an unmet treatment need, while campaigners w...
by Hepatitis C Research and News on Jun 14, 2014

Hepatitis C Virus Therapy in the Direct Acting Antiviral Era

Current Opinion in Gastroenterology Mitchell L. Shiffman Curr Opin Gastroenterol. 2014;30(3):217-222. Abstract and Introduction Abstract Purpose of review: The evolution of treatment for patients with chronic hepatitis C virus (HCV) is evolving...
by Hepatitis C Research and News on May 16, 2014

The Rapid Evolution of Treatment Strategies for Hepatitis C

PDF Provided by NATAP Am J Gastroenterol advance online publication, 15 April 2014; doi: 10.1038/ajg.2014.66 Andrew J. Muir , MD, MHS1 Hepatitis C virus (HCV) treatment took a major step forward at the end of 2013 with the approvals of the s...

Germany's IQWiG backs Sovaldi for hepatitis C genotype 2 only (7% of all HCV people in Germany have genotype 2)

Press Release 2014-05-02 Sofosbuvir: indication of added benefit for specific patients Better virologic response in genotype 2 chronic hepatitis C / extent of added benefit unclear / no suitable data for other virus types The drug sofosbuvir has...

$1,000-a-Day Hepatitis C Miracle Drug Gets a Major Price Cut, Just Not In the U.S.

Provided by The Wire By Polly Mosendz 4 hours ago Health department workers in New Hampshire set up a temporary clinic to handle a hepatitis C outbreak in 2012. (AP PHOTO/JIM COLE) India, Egypt and Brazil have secured access to Sovaldi, the i...
by Hepatitis C Research and News on Apr 11, 2014

Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy

-- Results Demonstrate Efficacy of Sovaldi-Based Regimen in GT1 Infected Patients Who Failed Prior Therapy with Other Direct Acting Antivirals-- -- Data Support Retreatment with Sovaldi-Based Regimen in GT2 or GT3 Infected Patients Who Failed Prior...
by Hepatitis C Research and News on Apr 10, 2014

EASL – Cost tops the agenda as hepatitis C enters post-interferon world

Provided by EP Vantage Date April 09, 2014 Scientific questions usually dominate medical meetings – except for the hepatitis C field, in which a long-awaited drug costs $1,000 a day and has cast a long shadow over global access. So it is with Eur...

A Call For Pricey Treatment For Millions With Hepatitis-C

Provided by Kaiser Health News By Richard Knox April 9th, 2014, 8:43 AM Authors of the first-ever global hep-C guidelines went big Tuesday, advocating for worldwide use of two of the most expensive specialty drugs in the world. The new gui...

Gilead aims to license hepatitis C drug to 3-4 Indian firms

By Ben Hirschler LONDON  Tue Apr 8, 2014 11:42am EDT (Reuters) - Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 develo...

Exclusive: Costs to public of $84,000 hep C drug ‘outrageous' - Kaiser

By Deena Beasley LOS ANGELES  Wed Apr 2, 2014 3:41pm EDT (Reuters) - Kaiser Permanente, the biggest U.S. health maintenance organization, said it is using Gilead Sciences' new hepatitis C drug, Sovaldi, even though its $84,000 treatment pric...

Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment

Clinical Liver Disease Volume 3, Issue 3 March 2014 Pages 65–68 M. Valerie Lin M.D., Raymond Chung M.D. First published: March 2014 Full publication history DOI: 10.1002/cld.332 Citing literature From the Gastrointestinal Unit, Liver Center a...

Gilead says has discounted hepatitis C drug for some health plans

By Deena Beasley Sat Mar 29, 2014 12:13pm EDT (Reuters) - Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview. Th...
by Hepatitis C Research and News on Mar 31, 2014

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals

Hepatology Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.) Viral Hepatitis Liesl M. Hagan1,*, Mark S. Sulkowski2 and Raymond F. Schinazi1 DOI: 10.1...
by Hepatitis C Research and News on Mar 28, 2014


Trending Topics

Close